The complement system, which is made up of more than 30 serum and cell surface components, works with the innate and acquired immune systems to recognize and get rid of pathogens. Following the activation of the complement system, a series of events involving proteolysis and assembly lead to the cleavage of the third complement component (C3). The activation pathway refers to the cascade that leads to C3 cleavage. The classical, lectin, and alternative pathways are the three types of activation.
The complement cascade is a double-edged sword that causes phagocytosis and inflammation while also providing defense against viral and bacterial invasion. If complement is not properly controlled, it can cause significant pathological damage to erythrocytes (hemolysis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and blood vessels (vasculitis).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74793 | 3-O-(2'E,4'Z-Decadienoyl)ingenol (3-O-(2'E,4'Z-Decadienoyl) ingenol) | 84680-59-1 | 3-O-(2'E,4'Z-Decadienoyl)ingenol is a naturally occurring diterpene with significant anti-complement activity with IC50 of 89.5 μM. |
|
V74774 | 3-Phenoxybenzaldehyde (m-Phenoxybenzaldehyde) | 39515-51-0 | 3-Phenoxybenzaldehyde has weak inhibitory activities on the classical pathway of complement and hemolytic activity. |
![ADH-503 [(Z)-Leukadherin-1 choline]](http://www.invivochem.com/upload/0201/6374234369832504391052898030.png)
|
V37572 | ADH-503 [(Z)-Leukadherin-1 choline] | 2055362-74-6 | ADH-503[(Z)-Leukadherin-1 choline] is a novel, potent, selective, orally bioactive and allosteric agonist of the integrin CD11b to mitigate myeloid cell immunosuppression. |
|
V40131 | ADH-503 free base | 2055362-72-4 | ADH-503 free base [(Z)-Leukadherin-1]is a novel, potent, selective,orally bioactive and allostericagonist of the integrin CD11b to mitigate myeloid cell immunosuppression. |
|
V77244 | ARC186 | ARC 186 is a nucleic acid aptamer and a potent complement inhibitor that works by blocking C5 activation catalyzed by invertase. | |
|
V86833 | ARC186 sodium | ARC186 (sodium) is a PEGylated nucleic acid aptamer. | |
|
V77228 | ATWLPPR Peptide TFA | ATWLPPR Peptide TFA is a selective neuropilin-1 (NRP-1) inhibitor that can inhibit the binding of VEGF165 to NRP-1 and can be used for angiogenesis research. | |
|
V74790 | Avacincaptad pegol | 1613641-69-2 | Avacincaptad pegol (Izervay) is a nucleic acid aptamer that works as a C5 complement inhibitor to reduce inflammation-related retinal pigment epithelial (RPE) damage. |
|
V86831 | C1s-IN-1 | 1016866-61-7 | C1s-IN-1 (compound A1) is a selective and competitive inhibitor of C1s. |
|
V77176 | C3a (70-77) (TFA) (Complement 3a (70-77) (TFA)) | C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a and displays C3a specificity and 1 to 2% bioactivity. | |
|
V74780 | C3a receptor agonist 1 | 944997-60-8 | C3a receptor agonist 1 (compound benzoacetamide) is a potent C3a receptor agonist. |
|
V74775 | C5a Anaphylatoxin (human) | 1816940-05-2 | C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. |
|
V74795 | C5a Receptor agonist, mouse, human | 144555-06-6 | C5a Receptor agonist, mouse, human is a biologically active peptide. |
|
V86829 | C5aR1 antagonist 1 | 2365325-67-1 | C5aR1 antagonist 1 (compound 7e) is an orally available C5aR antagonist. |
|
V86830 | C5aR1 antagonist 2 | 2365161-92-6 | C5aR1 antagonist 2 (Compound 6a) is an orally active C5a receptor 1 (C5aR1) antagonist that effectively inhibits C5a-induced increases in neutrophil counts. |
|
|
V86828 | Cemdisiran sodium | Cemdisiransodium is a GalNAc-conjugated siRNA that is used to study complement-mediated diseases by inhibiting the production of complement 5 (C5) protein in the liver. | |
|
V74799 | Citrostadienol | 474-40-8 | Citrostadienol is a steroid compound with anti-inflammatory and anticomplementary activities. |
|
V78850 | Complement C1s-IN-1 | Complement C1s-IN-1 is a specific, orally bioactive C1s inhibitor that crosses the BBB (blood-brain barrier) with IC50 of 36 nM. | |
|
V3627 | Complement factor D-IN-2 | 1903742-34-6 | Complement factor D-IN-2 (extracted fromWO2015130838A1, compound 190) is an inhibitor of complement factor D with the potential to be used for treating autoimmune diseases. |
|
V77143 | Compstatin TFA | Compstatin TFA is a 13-residue cyclic peptide that is a potent inhibitor of complement system C3 and is species-specific. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
